BlackRock
PAND

BlackRock’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

BlackRock’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,074,554
Closed -$64.5M – 5654
2021
Q1 		$64.5M Buy
1,074,554
+370,884
+53% +$13.4M ﹤0.01% 2457
2020
Q4 		$10.4M Buy
703,670
+284,799
+68% +$3.96M ﹤0.01% 3339
2020
Q3 		$4.8M Buy
+418,871
New +$7.16M ﹤0.01% 3588

BlackRock's PAND Position: Q2 2021 in Review

BlackRock sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 1,074,554 shares — an estimated $64.5M sold.

BlackRock first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $64.5M in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

  • BlackRock reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • BlackRock sold 1,074,554 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $64.5M.
  • BlackRock first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • BlackRock's Pandion Therapeutics Inc. Common Stock position peaked at $64.5M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on BlackRock's 13F filing for Q2 2021, filed 11 Aug 2021.